ASPIRA WOMEN'S HEALTH INC (AWH) 0.51 +0.01 (+2.8%)
0.51 +0.01 (+2.8%)
US04537Y1091 - Common Stock - Premarket: 0.5 -0.01 (-1.96%)
Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights
Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021 Preliminary results...
Aspira Women’s Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses
Provides clinical validation for the use of OvaWatchSM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses ...
Aspira Women’s Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio
Expanded Medicare coverage for multi-marker testing, including Ova1Plus® and OvaWatchSM, through the 2023 Omnibus Spending Bill Granted a new PLA Code...
Aspira Women’s Health Announces the Commercial Launch of OvaWatch(SM)
AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on...
Aspira Women’s Health Reports Third Quarter 2022 Financial Results
Increased year-over-year product revenue by 26% to $2.0 million and year-over-year product volume by 29% to 5,524 units Reconfirmed fourth quarter launch...
Aspira Women’s Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022
AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced...
Aspira Women’s Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women
Data demonstrates the accuracy of Aspira’s multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125...
Aspira Women’s Health Inc. Announces Proposed Public Offering
AUSTIN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company...
Aspira Women’s Health Hosting Women’s Health Webinar on Ovarian Cancer Risk Assessments Utilizing Multivariant Index Assay
KOL Event to take place on Wednesday, August 24th at 12:00pm ET...
Aspira Women’s Health Reports Second Quarter 2022 Financial Results
Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber...
Aspira Women’s Health to Announce Second Quarter 2022 Financial Results and Host Conference Call on Wednesday, August 10
AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on...
Aspira Women’s Health Announces Appointment of Two New Board Members
Seasoned Directors further strengthen Board with decades of industry and leadership experience...
Aspira Women’s Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer
Paper published in the June online issue of JCO Clinical Cancer Informatics...